Vyriad, Inc.
Clinical trials sponsored by Vyriad, Inc., explained in plain language.
-
Engineered virus joins forces with immunotherapy to fight resistant cancers
Disease control OngoingThis phase 2 trial tests whether a modified virus (VV1) combined with the immunotherapy drug cemiplimab can shrink tumors in people with colorectal cancer, head and neck squamous cell carcinoma, or melanoma that has stopped responding to checkpoint inhibitor treatment. The virus …
Phase: PHASE2 • Sponsor: Vyriad, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Virus and immunotherapy combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of a modified virus (VSV-IFNβ-NIS) and immunotherapy drugs (pembrolizumab or ipilimumab+nivolumab) in people with advanced solid tumors, including non-small cell lung cancer, neuroendocrine carcinoma, and renal cell carcinoma. The virus …
Phase: PHASE1, PHASE2 • Sponsor: Vyriad, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:34 UTC